false000127121400012712142021-05-142021-05-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2021
Intersect ENT, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-36545 20-0280837
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
1555 Adams Drive Menlo Park, California
 94025
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 641-2100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
symbol
 Name of each exchange
on which registered
Common stock, $0.001 par value XENT The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 7.01
Regulation FD Disclosure
As previously disclosed on May 10, 2021, on April 26, 2021, Intersect ENT (the “Company”) was notified by a European Notified Body (the “Notified Body”) of deficiencies in certain policies and processes after an audit at the Company’s Menlo Park, CA facility. As a result of the deficiencies, the Company’s CE Marks for PROPEL and PROPEL Mini were suspended while it completed necessary remediation activities and submitted a response. During the suspension, the Company remained permitted to sell existing inventory located in the European Union. On May 7, 2021, the Company completed its formal response and on May 10, 2021 submitted that response in a filing to the Notified Body. On May 18, 2021, the Company received notification from the Notified Body that the suspension was lifted effective May 14, 2021 and that it may continue to use its CE Marks.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 Intersect ENT, Inc.
Dated: May 18, 2021 
 By: /s/ Patrick A. Broderick
  Name: Patrick A. Broderick
  Title: Executive Vice President, General Counsel